Researchers at Georgia Tech, led by School of Chemistry and Biochemistry Professor M.G. Finn , along with researchers from MIT, revealed a new strategy for enabling immune system mobilization against cancer cells. The work, which appears in ACS Nano, produces exactly the type of anti-tumor immunity needed to function as a tumor vaccine - both prophylactically and therapeutically. Finn's research, along with two other groups, had previously identified a synthetic DC-SIGN binding group that directed cellular immune responses when used to decorate virus-like particles. But it was unclear whether this method could be utilized as an anticancer vaccine. Collaboration between researchers in the labs at MIT and Georgia Tech demonstrated that in fact, it could.